Gibson Dwight Audley Konrad
Gibson Dwight Audley Konrad's purchase track record
Gibson Dwight Audley Konrad has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/27/2026 | AMRZ | $244 | pending | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Interface Inc. to Host Q3 2026 Earnings Call on Nov 6. Interface Inc. announced it will hold its third-quarter 2026 earnings conference call on November 6, 2026. The company was also highlighted in recent Zacks.com coverage alongside other stocks. With the stock trading near the top of its 52-week range, investors may look to this call for updates on cash flow and business performance.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
BXC: BlueLinx Expands Deal with Westlake Royal Products. BlueLinx announced an expanded partnership with Westlake Royal Building Products, adding exclusive distribution of Kleer® PVC trim and extending market reach for TruExterior® siding and trim. The agreement broadens BlueLinx’s product offerings and could enhance its presence in the building materials market. In a separate note, Citizens Research initiated coverage of BlueLinx with a Market Perform rating.
Transaction History
| AMRZ | ▲ Buy | Open Market | 5 | $244 | 8/27/2026 | View on chart |
| TILE | ▲ Buy | Grant | 4,461 | $0 | 5/19/2026 | View on chart |
| AMRZ | ▼ Sell | Tax Withholding | 740 | $42K | 4/21/2026 | View on chart |
| AMRZ | ▲ Buy | Grant | 2,976 | $0 | 4/21/2026 | View on chart |
| AMRZ | ▲ Buy | Grant | 2,958 | $0 | 8/11/2025 | View on chart |
| TILE | ▲ Buy | Grant | 6,480 | $0 | 5/15/2025 | View on chart |
| TILE | ▲ Buy | Grant | 7,015 | $0 | 5/13/2024 | View on chart |
| TILE | ▲ Buy | Grant | 14,608 | $0 | 5/15/2023 | View on chart |
| BXC | ▲ Buy | Option Exercise | 44,160 | — | 3/29/2023 | View on chart |
| BXC | ▼ Sell | Tax Withholding | 18,339 | $1.2M | 3/29/2023 | View on chart |
| BXC | ▲ Buy | Option Exercise | 57,720 | — | 6/7/2022 | View on chart |
| BXC | ▼ Sell | Tax Withholding | 25,762 | $2.3M | 6/7/2022 | View on chart |
| TILE | ▲ Buy | Grant | 8,442 | $0 | 5/17/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
JP Morgan cuts Amrize price target to $48, maintains Neutral
JP Morgan has lowered its price target for Amrize to $48 while keeping a Neutral rating. This move comes as the company prepares to announce its third-quarter 2026 financial results. Recent reports also highlight the firm's regional scale and pricing power, though the current analyst target sits below the average consensus of $47.20.
JP Morgan cuts Amrize price target to $48, maintains Neutral. JP Morgan has lowered its price target for Amrize to $48 while keeping a Neutral rating. This move comes as the company prepares to announce its third-quarter 2026 financial results. Recent reports also highlight the firm's regional scale and pricing power, though the current analyst target sits below the average consensus of $47.20.